insights_auto
Why is DUL down 5.34%?
Dive Deeperchevron_right
DUL:ETR
Alnylam Pharmaceuticals, Inc.
€198.70
arrow_downward
-5.34%(-11.20) 1D
Oct 2, 5:35:33 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DUL...
Open
€206.70
High
€211.50
Low
€198.70
Mkt. cap
29.40B
Avg. vol.
31.00
Volume
206.00
52-wk high
€417.40
52-wk low
€177.10
No. of employees
2K
Open
€206.70
High
€211.50
Low
€198.70
Mkt. cap
29.40B
Avg. vol.
31.00
Volume
206.00
52-wk high
€417.40
52-wk low
€177.10
No. of employees
2K
News stories
From web sources and news partners
Investing.com Canada
·
10 hours ago
Form 144 ALNYLAM PHARMACEUTICALS For: 2 October By Investing.com
Stock Titan
·
10 hours ago
An Alnylam (ALNY) officer proposes a $399K share sale that includes shares to cover an equity-award tax bill.
Simply Wall Street
·
1 day ago
Alnylam Pharmaceuticals (ALNY) Stock Looks Above Fair Value As Shares Fell 49%
TipRanks
·
1 day ago
Alnylam Stock Sinks as Wall Street Turns Cautious
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.